UK probes mega AstraZeneca deal for US biotech firm

Credit: Unsplash/CC0 Public Domain

Britain's competition watchdog on Tuesday said it was investigating the planned purchase of US biotech company Alexion by COVID vaccine-maker AstraZeneca in a deal worth $39 billion.

In a brief statement, the Competition and Markets Authority said it was looking at whether the deal would "result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services".

The planned tie-up, aimed at boosting AstraZeneca's work on immunology, was announced in December as the London-listed company began to roll out the coronavirus vaccine it developed with the University of Oxford.

Explore further

AstraZeneca buying drug developer Alexion for $39 billion

© 2021 AFP

Citation: UK probes mega AstraZeneca deal for US biotech firm (2021, May 25) retrieved 2 December 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors